乳腺癌患者化疗前后血清sVCAM-1和CA15-3表达及其临床意义  

CONCENTRATION AND CLINICAL SIGNIFICANCES OF SERUM SVCAM-1 AND CA15-3 IN PATIENTS WITH BREAST CANCER RECEIVING CHEMOTHERAPY

作　　者：刘艳[1] 李积德[2] 

机构地区：[1]青海大学医学院 [2]青海大学附属医院肿瘤内科

出　　处：《青海医学院学报》2007年第3期170-174,共5页Journal of Qinghai Medical College

摘　　要：目的观察可溶性血管细胞粘附分子-1(sVCAM-1)和癌相关糖蛋白抗原(CA15-3)在乳腺癌患者化疗前后浓度的变化,探讨二者水平与临床分期、转移部位的关系,并初步探讨晚期转移性乳腺癌患者治疗效果与二者水平变化的关系。方法采用酶联免疫吸附试验(ELISA)和化学发光免疫法(CLIA)测定15例健康人、30例早期乳癌患者(Ⅰ、Ⅱ)、40例晚期乳癌患者(Ⅲ、Ⅳ)化疗前后sVCAM-1、CA15-3血清水平。结果治疗前,Ⅰ、Ⅱ期乳腺癌患者血清sVCAM-1和CA15-3浓度与健康者比较差异无显著性(P>0.05);Ⅲ、Ⅳ期乳腺癌患者血清sVCAM-1和CA15-3浓度均显著高于健康者,并随着分期渐晚二者浓度逐渐升高,差异有显著性(P<0.05),其中,乳腺癌患者各组血清CA15-3阳性率均显著高于正常对照组(P<0.05)。检测了12例内脏转移和7例骨转移晚期乳腺癌患者血清sVCAM-1和CA15-3水平,发现内脏转移组二者水平高于骨转移组,但差异无显著性(P>0.05)。治疗后,各乳腺癌患者组血清sVCAM-1和CA15-3水平均较前降低,Ⅰ、Ⅱ组差异无显著性,Ⅲ、Ⅳ组差异显著(P<0.05),转移复发乳腺癌患者下降尤为明显。24例晚期转移患者采用以TA为主的联合方案化疗,治疗后19例患者疗效评价为PR+CR,化疗后sVCAM-1和CA15-3水平均下降,差异显著(P<0.001)。结论乳腺癌患者血清sVCAM-1和CA15-3水平与病期早晚及治疗反应相关,与转移部位关系不明显,二者有可能成为评价乳腺癌临床分期和血清学疗效的指标。Objective To investigate serum sVCAM - 1 and CA - 153 levels in patients with breast cancer receiving chemotherapy, to explore their correlations with clinical stage, metastatic sites, and sVCAM - 1 ,CA15 - 3 levels . Methods The serum levels of sVCAM - 1 and CA15 -3 were determined respectively by enzyme linked im- munosorbent assay（ELISA） and chemiluminescence immunoassay （CLIA） in 15 health women,30 cases of earlierbreast cancer patients （phase Ⅰand Ⅱ ）, 40 cases of advanced chemotherapy. Results Before chemotherapy, sVCAM -1 and breast cancer patients （ phase 11 and IV ） receiving CA15 - 3 values in the sera of patients with earlier breast cancer（phase Ⅰ and Ⅱ） were not significantly higher in comparison with the results obtained in the control group （ P 〉 0.05 ）, but two factors in advanced beast cancer patients were significantly higher compared with the control group （ P 〈 0.05 ） ; The positive rates of CA15 - 3 in patients with breast cancer （ Ⅰ, Ⅱ, Ⅲand IV ） were significantly higher（ P 〈0.05 ） than control. With clinical stage advanced , their values were increased. Compa- ring 12 cases patients with viscera metastasis with 7 cases patients with bone metastasis, the two factors in patients with viscera metastasis were higher, but the difference were not significant （ P 〉 0.05）. After chemotherapy, The serum levels of sVCAM - 1 and CA15 -3 declined in advanced breast cancer patients （ P 〈 0.05 ）, but the difference in earlier breast cancer（ Ⅰ, Ⅱ）were not significant（ P 〉 0.05 ）. Through predominance of TA combined chemotherapy, predicting the effect of chemotherapy for 24 cases remote metastatic breast cancer patients , 19 cases remote metastatic breast cancer patients are valid（ PR ＋ CR） ,and The serum levels of sVCAM - 1 and CA15 -3 were declined , the difference was significant （ P 〈 0. 001 ）. Conclusions The serum levels of sVCAM - 1 and CA15 - 3 are correlated with the clinical stage and the treatment effec

关 键 词：乎乙腺癌 SVCAM-1 CAL5-3 

分 类 号：R737.9[医药卫生—肿瘤]